A Prospective, Randomized Clinical Trial Comparing Rivaroxaban vs Warfarin in High Risk Patients With Antiphospholipid Syndrome
Phase of Trial: Phase III
Latest Information Update: 05 May 2017
At a glance
- Drugs Rivaroxaban (Primary)
- Indications Antiphospholipid syndrome
- Focus Therapeutic Use
- Acronyms TRAPS
- 02 May 2017 Planned End Date changed from 1 Dec 2018 to 1 Dec 2020.
- 02 May 2017 Planned primary completion date changed from 1 Dec 2018 to 1 Dec 2020.
- 27 Apr 2015 Patient's inclusion criteria changed to include the patients with age 18-75 years ( previously which was 18-60 years) as reported by ClinicalTrials.gov record.